HHS says supply could run out by the end of this month.
The U.S. government's current supply of remdesivir will run out at the end of this month, CNN reported.
The amount of people who need the medication outnumbered the supply by a 2-to-1 ratio, according to The Wall Street Journal. Gilead Sciences and the Department of Health and Human Services distributed remdesivir for between 40,000 and 74,000 hospitalized patients.
Related: Top 3 COVID-19 stories this week
The government’s last shipment of remdesivir will go out the week of June 29, Robert Kadlec, MD, assistant secretary for preparedness and response at HHS, told CNN.
"Right now, we're waiting to hear from Gilead what is their expected delivery availability of the drug as we go from June to July," Kadlec said. "We're kind of not in negotiations, but in discussions with Gilead as they project what the availability of their product will be,” Kadlec said.
Related: FDA: Fraudulent COVID-19 medical products abound
"Whatever the supply may be, there may not be enough for everyone who may need it,” he added.
However, the government has been working to help Gilead "with some of their supply chain challenges in terms of raw materials and being able to accelerate the process,” Kadlec told CNN.
Gilead said it expects to have more than 500,000 remdesivir treatment courses available by October, and more than a million by December.
Read more: COVID-19 vaccines could be ready this year, plus other top news
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More